TopicNeurology

Brain changes associated with Alzheimer’s disease can now be studied in living people. Mass General researchers imaged cognitively normal people who are destined to develop AD due to a rare genetic mutation. Their goal: to discover how soon brain changes are present before symptoms begin and how soon preventive treatments could be initiated.

Neurologists at Mass General explore the case of a woman who endured gait disturbance, cognitive impairment and urinary incontinence for 2 years before she was diagnosed with normal-pressure hydrocephalus and successfully treated with surgical shunting.

Neurologists at Massachusetts General Hospital have determined that tau fibril formation, one of the pathological hallmarks of Alzheimer's disease, disrupts molecular transport in neurons—suggesting a potential new therapeutic strategy.

In this video, Jeffery Schweitzer, MD, PhD, discusses his research using stem cell technology to restore normal function in patients with movement disorders. He believes this technology may be able to improve outcomes for patients with tremor, Parkinson's disease and dystonia.

A randomized, active-comparator, double-blind, multinational phase 3 trial has established the efficacy and safety of fingolimod for patients with relapsing multiple sclerosis who are 10 and older. The drug is now FDA approved for that population.

Neuroscience Care at Mass General

Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.